Compare ALEMBIC PHARMA with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs ABBOTT INDIA - Comparison Results

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA ABBOTT INDIA ALEMBIC PHARMA/
ABBOTT INDIA
 
P/E (TTM) x 16.8 47.1 35.6% View Chart
P/BV x 6.7 15.4 43.3% View Chart
Dividend Yield % 0.6 0.4 128.1%  

Financials

 ALEMBIC PHARMA   ABBOTT INDIA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
ABBOTT INDIA
Mar-19
ALEMBIC PHARMA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs6648,834 7.5%   
Low Rs4125,458 7.6%   
Sales per share (Unadj.) Rs208.71,731.1 12.1%  
Earnings per share (Unadj.) Rs31.0211.9 14.6%  
Cash flow per share (Unadj.) Rs37.1219.9 16.9%  
Dividends per share (Unadj.) Rs5.5065.00 8.5%  
Dividend yield (eoy) %1.00.9 112.3%  
Book value per share (Unadj.) Rs144.2945.2 15.3%  
Shares outstanding (eoy) m188.5221.25 887.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.64.1 62.5%   
Avg P/E ratio x17.433.7 51.5%  
P/CF ratio (eoy) x14.532.5 44.6%  
Price / Book Value ratio x3.77.6 49.4%  
Dividend payout %17.730.7 57.8%   
Avg Mkt Cap Rs m101,461151,848 66.8%   
No. of employees `000NA3.5 0.0%   
Total wages/salary Rs m7,4674,356 171.4%   
Avg. sales/employee Rs ThNM10,555.5-  
Avg. wages/employee Rs ThNM1,249.9-  
Avg. net profit/employee Rs ThNM1,292.2-  
INCOME DATA
Net Sales Rs m39,34736,786 107.0%  
Other income Rs m941,133 8.3%   
Total revenues Rs m39,44137,919 104.0%   
Gross profit Rs m8,7366,047 144.5%  
Depreciation Rs m1,152169 681.0%   
Interest Rs m18423 818.2%   
Profit before tax Rs m7,4936,989 107.2%   
Minority Interest Rs m110-   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5682,485 63.1%   
Profit after tax Rs m5,8444,503 129.8%  
Gross profit margin %22.216.4 135.1%  
Effective tax rate %20.935.6 58.8%   
Net profit margin %14.912.2 121.3%  
BALANCE SHEET DATA
Current assets Rs m19,57727,610 70.9%   
Current liabilities Rs m14,8968,569 173.8%   
Net working cap to sales %11.951.8 23.0%  
Current ratio x1.33.2 40.8%  
Inventory Days Days9060 149.0%  
Debtors Days Days4527 165.5%  
Net fixed assets Rs m27,0971,057 2,563.8%   
Share capital Rs m377213 177.4%   
"Free" reserves Rs m26,81119,873 134.9%   
Net worth Rs m27,18820,086 135.4%   
Long term debt Rs m4,9930-   
Total assets Rs m47,77829,409 162.5%  
Interest coverage x41.7311.6 13.4%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.81.3 65.8%   
Return on assets %12.615.4 82.0%  
Return on equity %21.522.4 95.9%  
Return on capital %23.634.9 67.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m19,453369 5,272.3%   
Fx outflow Rs m6,0654,918 123.3%   
Net fx Rs m13,388-4,549 -294.3%   
CASH FLOW
From Operations Rs m8,1204,991 162.7%  
From Investments Rs m-7,556-2,570 294.0%  
From Financial Activity Rs m590-1,428 -41.3%  
Net Cashflow Rs m1,153993 116.1%  

Share Holding

Indian Promoters % 74.1 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 2.9 7.9 36.7%  
FIIs % 9.1 0.1 9,100.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 17.1 81.3%  
Shareholders   49,328 18,270 270.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   NEULAND LABS  DR. REDDYS LAB  NOVARTIS  UNICHEM LAB  PROCTER & GAMBLE HEALTH  

Compare ALEMBIC PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks 531 Points; Reliance Industries & IndusInd Bank Fall 5%(Closing)

Indian share markets witnessed huge selling pressure today and failed to hold on to their opening gains as profit booking and weakness across all sectors erased gains.

Related Views on News

AUROBINDO PHARMA at All Time High; BSE HEALTHCARE Index Up 1.0% (Market Updates)

Jan 25, 2021 | Updated on Jan 25, 2021

AUROBINDO PHARMA share price has hit an all time high at Rs 1,012 (up 9.4%). The BSE HEALTHCARE Index is up by 1.0%. Among the top gainers in the BSE HEALTHCARE Index today are AUROBINDO PHARMA (up 9.4%) and ABBOTT INDIA (up 0.8%). The top losers include THYROCARE TECHNOLOGIES (down 0.1%) and LAURUS LABS (down 0.2%).

ALEMBIC PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 13.8% (Quarterly Result Update)

Jan 19, 2021 | Updated on Jan 19, 2021

For the quarter ended December 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 13.8% YoY). Sales on the other hand came in at Rs 13 bn (up 8.7% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 30.0% (Quarterly Result Update)

Oct 23, 2020 | Updated on Oct 23, 2020

For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY21); Net Profit Up 54.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 54.2% YoY). Sales on the other hand came in at Rs 11 bn (up 6.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY20); Net Profit Down 2.0% (Quarterly Result Update)

Jun 9, 2020 | Updated on Jun 9, 2020

For the quarter ended March 2020, ABBOTT INDIA has posted a net profit of Rs 1 bn (down 2.0% YoY). Sales on the other hand came in at Rs 10 bn (up 6.1% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

Buzzing Sectors Before Budget 2021(Fast Profits Daily)

Jan 12, 2021

The budget is just a few weeks away. Which stocks can you expect to move? Find out in this video.

Here's Why Smallcaps Could Be Your Best Investment in 2021(Profit Hunter)

Jan 12, 2021

Select smallcaps hold a great potential to become the multibaggers of tomorrow. Here's how you could get in early into these stocks.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Jan 25, 2021 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 8-QTR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS